|
Letosteine
|
|
| Systematic (IUPAC) name | |
| 2-{2-[(2-ethoxy-2-oxoethyl)thio]ethyl}-1,3-thiazolidine-4-carboxylic acid | |
| Identifiers | |
| CAS number | |
| ATC code | R05 |
| PubChem | |
| Chemical data | |
| Formula | C10H17NO4S2 |
| Mol. mass | 279.378 g/mol |
| Synonyms | 2-[2-(ethoxycarbonylmethylsulfanyl)ethyl]-1,3-thiazolidine-4-carboxylic acid |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Letosteine is a mucolytic patented (U.S. patent 6987120) by Piero del Soldato of Milan, Italy.[1] He filed his application in 2000.
References
|
||||||||||||||||
This entry is from Wikipedia, the leading user-contributed encyclopedia. It may not have been reviewed by professional editors (see full disclaimer)




